• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan

Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan

by Elizabeth | Sep 22, 2025 | News, News

Reduction of the Company’s debt from €40 million to €12 million, spread over 10 years  Capital increase of at least €5 million post-plan adoption, with the issuance of stock warrants (BSAs) to finance the Company to profitability  Issuance of BSAs to all...
Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan

Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion 

by Elizabeth | Sep 18, 2025 | News, News

Paris, Boston and Sydney, September 18, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the Australian Register of Therapeutic Goods (ARTG). This listing, secured...
Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 

Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 

by Elizabeth | Sep 8, 2025 | News

New letter published by the AFS highlights Cellvizio’s superiority to conventional tools for detecting pre-cancerous tissue and dysplasia  Paris and Boston, September 08, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®,...
See Beyond the Surface: How Cellvizio® Redefines Accuracy for Detecting and Treating Cancers

See Beyond the Surface: How Cellvizio® Redefines Accuracy for Detecting and Treating Cancers

by Elizabeth | Aug 13, 2025 | Press Coverage

This comprehensive feature written by Daryl C. Donatelli, MBA, President, U.S. & Head of Global Marketing, Mauna Kea Technologies explores the Cellvizio platform and details how the technology is transforming cancer detection and treatment across gastroenterology...
Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan

Mauna Kea Technologies Reports First Half 2025 Revenue 

by Elizabeth | Jul 28, 2025 | News

On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2  Record U.S. sales productivity despite ongoing safeguard procedure  Total revenue down 5% amid weaker EMEA and ROW sales results  Further steps taken to improve Mauna Kea...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase 
  • Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates 
  • Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan 
  • Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring 
  • Mauna Kea Technologies Announces 2025 Half-Year Results 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}